Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer

Not Applicable

Terminated

• Conditions: Breast Cancer, Invasive Ductal
• Interventions: Device: Philips Sonalleve® MR-HIFU Breast Therapy System

• Registration Number: NCT03560102
• Lead Sponsor: Kantonsspital Winterthur KSW

Brief Summary

The purpose of the study is to evaluate the efficacy of a dedicated Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) unit in ablating breast cancer by comparing MR imaging and pathologic specimen after resection.

Single-center, single-arm, non-randomized trial

Detailed Description

The dedicated MR-HIFU unit has been shown to be safe and feasible to ablate breast tissue.

The planned study should address the possibility to completely ablate breast cancer with the dedicated breast MR-HIFU unit. The result of the MR-HIFU therapy should be monitored by imaging (contrast enhanced MRI) as well as with histopathological correlation after surgery.

The patient population would consist of female patients with proven breast cancer scheduled for surgical lumpectomy or mastectomy.

The idea is to evaluate a minimal invasive method to treat breast cancer as a potential alternative to surgical resection in the future

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-05-14
• Study First Submitted QC: 2018-06-15
• Study First Posted: 2018-06-18
• Study Start: 2020-01-13
• Primary Completion: 2020-02-05
• Study Completion: 2020-02-05
• Status Verified: 2021-09
• Results First Submitted: 2021-09-23
• Results First Submitted QC: 2021-09-23
• Last Update Submitted: 2021-09-23
• Results First Posted: 2021-10-22
• Last Update Posted: 2021-10-22

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 1

Inclusion Criteria

• Informed Consent as documented by signature
• World Health Organization (WHO) performance status≤ 2
• Body weight ≤ 80 kg
• Biopsy proven invasive breast cancer with a size of ≤3.0cm (TNM classification: cT1-2 N0-2 MX ).
• Histological type of tumor: invasive ductal carcinoma (IDC)
• Patient is scheduled for surgical resection of tumor at study site
• Tumor location within the reach of the HIFU transducers with the patient in prone position; distance from skin and pectoral muscle to the tumor ≥ 1.0 cm.
• Target breast fits in the cup of the dedicated MR-HIFU breast system

Read More

Exclusion Criteria

• neoadjuvant systemic therapy
• prior radiotherapy in target breast
• contraindications for MRI
• contraindication for application of gadolinium-based contrast agent
• contraindication for procedural sedation analgesia
• macro-calcifications in or around the targeted tumor
• scar tissue or surgical clips in the direct path of the ultrasound beams
• Women who are pregnant or breast feeding,
• Intention to become pregnant during the course of the study,
• Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.
• Known or suspected non-compliance, drug or alcohol abuse,
• Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
• Participation in another study with investigational drug/device within the 30 days preceding and during the present study,
• Previous enrolment into the current study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MR-HIFU treatment	Philips Sonalleve® MR-HIFU Breast Therapy System	Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat\& resect model

Primary Outcome Measures

Name	Time	Method
Accuracy of MRI as Method for Assessment of Quantitative Treatment Success (Correlation With Results of the Histopathological Analysis Performed as Reference Method)	Day 14	Quantitative assessment: Correlation between MRI and histopathology results (volume of necrosis)

Secondary Outcome Measures

Name	Time	Method
Assessment of Treatment Efficacy	Day 14	Effective treatment is defined as complete necrosis (100%) of targeted tumor including safety margin (\>1mm) (histopathological analysis).; Safety margin: measurement of smallest margin on histology and measurement of smallest margin on MRI. Parameter: Percentage of necrosis including safety margin

Trial Locations

Locations (1)

Kantonsspital Winterthur; 🇨🇭 Winterthur, Switzerland